Following the transaction, the Glenmark CNS commercial team in Poland will join Neuraxpharm Polska’s existing sales and marketing organization to create a strong player in the Polish CNS market, Neuraxpharm said in a press release.

Glenmark’s established portfolio of 20 proprietary CNS products in Poland comprise both prescription medicines and Consumer Healthcare products. The terms of the transaction were not disclosed.